-
Specialties
Board Certification
American Board of OphthalmologyPatient Rating
4.9 /5( out of 65 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety.
Patients are de-identified for confidentiality and patient privacy.July 21, 2024MORAN EYE CENTERVery thorough knowledgeable
July 18, 2024MORAN EYE CENTERshe was great just the wait is not good
July 18, 2024MORAN EYE CENTERDr. Craven is very kind, clear and concise in her explanations, and gentle with procedures.
July 09, 2024MORAN EYE CENTERShe is very kind and caring.
July 03, 2024MORAN EYE CENTERSee the prior review. But as only one of the 80 ocular oncologists in the US I was (am) in very good hands. I have nothing but trust in her expertise.
June 13, 2024MORAN EYE CENTERShe was informed about my condition and prepared with options for treatment. I appreciated how she included me in the decision making and accommodated my request for a hybrid treatment.
June 10, 2024MORAN EYE CENTERKnowledgeable, Professional, Personable, Patient
June 09, 2024MORAN EYE CENTERVery courteous, competent, knowledgeable, and professional
May 31, 2024MORAN EYE CENTERExplains plan for treatment in detail. Much appreciated.
-
Board Certification and Academic Information
Academic Departments Ophthalmology & Visual Sciences -Primary Board Certification American Board of OphthalmologyEducation history
Fellowship Medical Retina and Uveitis - Emory Eye Center Fellow Ocular Oncology and Pathology - Emory Eye Center Fellow Residency Ophthalmology - The Ohio State Ογ½ΆΚΣΖ΅ Wexner Medical Center Resident OhioHealth Riverside Methodist Hospital Transitional Internship Fellowship Ocular Oncology and Pathology - Emory Eye Center Fellow Medicine - Ογ½ΆΚΣΖ΅ of Cincinnati College of Medicine M.D. Other Training Deaf Studies and American Sign Language - Columbus State Community College Certificate Major: Biology with Specialization in Microbiology; Minor: Disability Studies - Ohio State Ογ½ΆΚΣΖ΅ B.S. Selected Publications
Journal Article
- Azarcon CP, Qiu RLJ, Sobol EK, Hubbard GB 3rd, Craven CM, Bergstrom CS, Wells JR (2022). Iodine-125 plaque brachytherapy for diffuse choroidal hemangioma. Retin Cases Brief Rep. ()
- Blyden K, Levine DA, Craven C, Hubbard GB (2022). A Novel Approach to Subretinal Fluid Drainage in Coats'-Related Exudative Retinal Detachment. Ophthalmic Surg Lasers Imaging Retina, 53(7), 407-409. ()
- Shabto JM, Price KW, Allen JC, Craven C, Jones JK, Wells J (2022). Spontaneous rupture of secondary iris inclusion cyst causing acute glaucoma and other ocular sequelae. Digit J Ophthalmol, 28(6), 26-30. ()
- Edwards W, Craven C, Turner JR, Grossniklaus H, Wells J (2022). Isolated hemangiopericytoma of the conjunctiva. Am J Ophthalmol Case Rep, 25, 101308. ()
- Azarcon CP, Craven CM, Wells JR (2021). Reactive Retinal Pigment Epithelium Hyperplasia in Presumed Ocular Histoplasmosis Syndrome. Ophthalmol Retina, 6(1), 36. ()
- Rali A, Xu LT, Craven C, Cohen JB, Yeh S, Grossniklaus HE, OKeefe GD (2021). Diagnostic retinal biopsy in the management of secondary non-CNS vitreoretinal lymphoma masquerading as viral retinitis: a case report. Int J Retina Vitreous, 7(1), 58. ()
- Schoenfield L, Janse S, Kline D, Aronow ME, Singh AD, Craven C, Abdel-Rahman M, Cebulla CM (2021). Estrogen Receptor Is Expressed in Uveal Melanoma: A Potential Target for Therapy. Ocul Oncol Pathol, 7(4), 303-310. ()
- Mendoza PR, Craven CM, Ip MH, Wilson MW, Coroneo MT, Grossniklaus HE (2018). Conjunctival Squamous Cell Carcinoma with Corneal Stromal Invasion in Presumed Pterygia: A Case Series. Ocul Oncol Pathol, 4(4), 240-249. ()
- Danish H, Ferris MJ, Balagamwala E, Switchenko JM, Patel KR, Choudhary M, Craven C, Mendoza P, Suh J, Bergstrom C, Grossniklaus HE, M Aaberg T Sr, Singh A, Crocker IR, Khan MK (2018). Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma. Melanoma Res, 28(2), 120-125. ()
- Rosenbaum JT, Choi D, Harrington CA, Wilson DJ, Grossniklaus HE, Sibley CH, Salek SS, Ng JD, Dailey RA, Steele EA, Hayek B, Craven CM, Edward DP, Maktabi AMY, Al Hussain H, White VA, Dolman PJ, Czyz CN, Foster JA, Harris GJ, Bee YS, Tse DT, Alabiad CR, Dubovy SR, Kazim M, Selva D, Yeatts RP, Korn BS, Kikkawa DO, Silkiss RZ, Sivak-Callcott JA, Stauffer P, Planck SR (2017). Gene Expression Profiling and Heterogeneity of Nonspecific Orbital Inflammation Affecting the Lacrimal Gland. JAMA Ophthalmol, 135(11), 1156-1162. ()
- Tran J, Craven C, Wabner K, Schmit J, Matter B, Kompella U, Grossniklaus HE, Olsen TW (2017). A Pharmacodynamic Analysis of Choroidal Neovascularization in a Porcine Model Using Three Targeted Drugs. Invest Ophthalmol Vis Sci, 58(9), 3732-3740. ()
- Patel KR, Prabhu RS, Switchenko JM, Chowdhary M, Craven C, Mendoza P, Danish H, Grossniklaus HE, Aaberg TM Sr, Aaberg T Jr, Reddy S, Butker E, Bergstrom C, Crocker IR (2017). Visual acuity, oncologic, and toxicity outcomes with (103)Pd vs. (125)I plaque treatment for choroidal melanoma. Brachytherapy, 16(3), 646-653. ()
- Hudson LE, Craven CM, Wojno TH, Grossniklaus HE (2016). Giant Chondroid Syringoma of the Lower Eyelid. Ophthalmic Plast Reconstr Surg, 33(2), e43-e44. ()
- Naguib MM, Craven C, Kozarsky A, Grossniklaus HE (2016). Neurothekeoma of the Cornea. Ocul Oncol Pathol, 2(4), 212-217. ()